Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 9/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | F12 | P00748 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30237030 | 1.00 | AHR (0.85) | AHRMEN1RAB9AKMT2ADAO | |
| SCHEMBL16627820 | 0.92 | AHR (1.00) | AHRMEN1RAB9AKMT2ADAO | |
| SCHEMBL16627821 | 0.91 | AHR (0.83) | AHRMEN1RAB9AKMT2ADAO | |
| SCHEMBL16627756 | 0.89 | AHR (1.00) | AHRMEN1RAB9AKMT2ADAO | |
| SCHEMBL30395644 | 0.89 | AHR (0.77) | AHRRAB9ADAOALDH1A1TSHR | |
| SCHEMBL25203869 | 0.89 | AHR (0.77) | AHRRAB9ADAOALDH1A1TSHR | |
| SCHEMBL16627752 | 0.89 | AHR (0.81) | AHRMEN1RAB9AKMT2ADAO | |
| SCHEMBL25221402 | 0.87 | AHR (0.78) | AHRRAB9AMAOBTSHRHTT | |
| SCHEMBL16627668 | 0.87 | AHR (0.77) | AHRMEN1RAB9AKMT2AMAOA | |
| SCHEMBL25224642 | 0.87 | AHR (1.00) | AHRMEN1RAB9AKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015050379-A1 | NOVEL QUINOLINONE DERIVATIVE AND USE THEREOF | 광주과학기술원 | 2015-04-09 | — | — | WO | disclosed |
| US-20110218199-A1 | PYRIDONEAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-08 | — | — | US | disclosed |
| EP-2190834-B1 | PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| EP-2065380-A1 | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218199-A1 | PYRIDONEAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | PLPBP, PNPO, PDXK | AHR 2317/4885MEN1 512/4885RAB9A 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.